|
|
|
|
|
Industry Audit + Company of the Year 2008
|
|
|
| By
Bill Trombetta
|
|
|
|
Pharm Exec's 7th annual review of the top companies. We slice and dice the numbers to see who's the best a what. (pdf)
|
|
|
|
Bolder is Better
|
|
|
| By
Charlene Prounis
|
|
|
|
As oncology grows, its advertising is growing up—leaving behind the mechanistic images and scientific themes of past campaigns
|
|
|
|
Place Your Bets
|
|
|
| By
Joanna Breitstein
|
|
|
|
The industry is a-changing. Here are eight seminal events that describe how.
|
|
|
|
Publish or Perish
|
|
|
|
FDAAA means that you need to register clinical trials—and not only for publication planning
|
|
|
|
How Do You Solve a Problem Like Manufacturing?
|
|
|
| By
Patrick Kager
,
David Williams
|
|
|
|
Outsourcing saves money—except when it doesn't. Here's how to decide what to do.
|
|
|
|
Unleash the Dragon 2
|
|
|
| By
Zhu Shen
|
|
|
|
Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign Affairs
|
|
|
| By
Jill Wechsler
|
|
|
|
FDA missteps and global outsourcing are drawing Congressional scrutiny and prompting new oversight approaches
|
|
|
|
|
|
|
|
|
Attack of the Junk
|
|
|
| By
Patrick Clinton
|
|
|
|
The United States makes the best medicines in the world. In days to come, that could be a problem.
|
|
|
|
|
|
|
|
|
The M&A Numbers
|
|
|
| By
Walter Armstrong
|
|
|
|
Young & Partners crunches pharma's filings for, the first half of '08. The results? Ask the Japanese
|
|
|
|
|
|
|
|
|
Tapping the Fount
|
|
|
| By
Sander A. Flaum
|
|
|
|
Leaders don't always manage to do the right thing, but they constantly strive to access the wellspring of integrity within them
|
|
|
|
|
|
|
|
|
The Orphan Opportunity
|
|
|
|
The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains
|
|
|
|
|
|
|
|
|
The New Code
|
|
|
|
Effective January 1st, sales reps will have a new standard for dealing with doctors the PhRMA way
|
|
|
|
|
|
|
|
|
Doing More With Less
|
|
|
| By
Sarah Houlton
|
|
|
|
In order to take a big step forward, GSK looks to employ smaller licensing deals and business units
|
|
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
